By Benjamin Horney (March 31, 2016, 3:54 PM EDT) -- Medivation Inc., a San Francisco-based biopharmaceutical firm focused on developing drugs that treat cancer, has tapped JPMorgan Chase & Co. to act as adviser as the company fields interest from suitors, Reuters reported on Thursday. Though Medivation does not intend to sell itself, the company has been approached a number of times during the early goings of 2016, the report noted, and the retention of JPMorgan is meant to ensure it is prepared for handling potential proposals. Medivation has a market capitalization of about $6.1 billion, the report noted, and some potentially interested parties could include Sanofi SA, Roche Holding AG and AstraZeneca PLC....